Product Document Searching Made Easy by 2D Code! | TCI Chemistry News June 2026 | [TCIPracticalExample] Oxidation Reaction of Heterocycles Using... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 129453-61-8 | Product Number: F1144
Fulvestrant
×
Purity: >98.0%(HPLC)
Synonyms:
- (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluorpentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3,17-diol
- ICI 182780
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 25MG |
$95.00
|
37 | 0 | Contact Us | |
| 100MG |
$273.00
|
12 | 28 | Contact Us |
* Please contact our distributors or
TCI
to order our products. The above prices do not include freight cost, customs, and other charges to the destination.
* The storage conditions are subject to change without notice.
| Product Number | F1144 |
Purity / Analysis Method 
|
>98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__3__2H__4__7F__5O__3S = 606.78 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Room Temperature (Recommended in a cool and dark place, <15°C) |
| Packaging and Container
|
100MG-Glass Bottle with Plastic Insert (View image), 25MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 129453-61-8 |
| Reaxys Registry Number | 7734375 |
| PubChem Substance ID | 468591825 |
| MDL Number | MFCD00903953 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Specific rotation [a]25 | +108 to +115 deg(365nm, C=2, methanol) |
Properties (reference)
| Solubility in water | Insoluble |
| Degree of solubility in water | 0.00001 g/l 25 °C |
| Solubility (soluble in) | Ethanol, Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H360 : May damage fertility or the unborn child. H362 : May cause harm to breast-fed children. H410 : Very toxic to aquatic life with long lasting effects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy and while nursing. P273 : Avoid release to the environment. P260 : Do not breathe dust. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P391 : Collect spillage. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | KG7623000 |
Transport Information:
| UN Number | UN3077 |
| Class | 9 |
| Packing Group | III |
| H.S.code* | 2937.29-000 |
Application
Fulvestrant: An Estrogen Receptors Antagonist with a Unique Structure and Mode of Action
Many breast cancers have estrogen receptors (ERs) and the growth of these tumors can be stimulated by estrogen. ER antagonists bind to ER and downregulate the ER protein in breast cancer cells. Fulvestrant (ICI 182,780) is an ER antagonist with a unique structure and mode of action. It not only binds competitively to the ER with high affinity, but also acts as a degradation inducer of ER with its long alkyl side chain. Therefore, fulvestrant has been reported to help circumvent resistance to “pure” ER antagonists, such as tamoxifen citrate [T2510]. For your reference, [D5471] is a key synthetic intermediate of fulvestrant. (The product is for research purpose only.)
References
- A Potent Specific Pure Antiestrogen with Clinical Potential
- Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens
- Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action (a review)
- Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women
- Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer
- Determination of Fulvestrant in Rat Plasma by LC-MS-MS: Application to a Pharmacokinetic Study
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Enter TCI Product Number
Enter KISHIDA Product Number
4-5 alphanumeric characters before the hyphen
7 alphanumeric characters
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
• The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
• Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
• If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
• Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Incorrect Lot Number. Please input only the 7 alphanumeric characters.
The requested analytical chart is not available. Sorry for the inconvenience.